Across TCGA pan-cancer cohorts, RAB40C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB40C data layer compared with 17 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RAB40C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB40C expression acts as an unfavorable survival marker.
CESC, PRAD, and UCEC are the cancer types where RAB40C Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.